GLX1 Antibody
Description
Introduction to GLI1 Antibodies
GLI1 antibodies are immunological tools designed to detect and analyze the GLI1 protein, a zinc finger transcription factor central to the Hedgehog (Hh) signaling pathway . GLI1 drives the expression of genes involved in cell proliferation, stem cell maintenance, and oncogenesis . Antibodies targeting GLI1 enable researchers to study its role in cancers (e.g., gliomas, non-small cell lung carcinoma) and developmental processes .
Antibody Structure
-
Format: Most GLI1 antibodies are monoclonal or polyclonal IgG isotypes .
-
Epitopes: Target regions include the C-terminal domain (e.g., Active Motif’s antibody) or amino acids 284–449 (e.g., Novus Biologicals’ 1B9F8 clone) .
-
Specificity: Validated against recombinant human/mouse GLI1 proteins, with cross-reactivity confirmed in Western blot (WB) and immunohistochemistry (IHC) .
Target Protein Features
Applications in Biomedical Research
GLI1 antibodies are utilized in:
Role in Cancer
-
Non-Small Cell Lung Cancer (NSCLC): GLI1 promotes epithelial–mesenchymal transition (EMT) and metastasis by stabilizing Snail, a key EMT regulator .
-
Neural Stem Cells: GLI1 maintains self-renewal capacity, with implications for glioma initiation .
Clinical Correlations
Product Specs
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
This antibody targets GLX1, an enzyme that catalyzes the conversion of the hemimercaptal intermediate (formed from methylglyoxal and glutathione) to S-lactoylglutathione.
Relevant studies demonstrate the impact of methylglyoxal (MG) on glyoxalase activity and plant growth:
- A study indicated that while 0.1 mM MG did not affect seedling growth, anthocyanin accumulation, MG levels, or glyoxalase activities (both I and II), concentrations of 0.5 mM and 1 mM inhibited seedling growth, induced anthocyanin accumulation, increased MG accumulation, and activated both glyoxalase I and II. PMID: 28117932
